BPC 157 nullifies the effect of L-NAME and brings all isoprenaline (+L-NAME) lesions markedly below control values (L-NAME + BPC 157 + isoprenaline
Researchers can adjust dosing and duration based on the desired therapeutic effects, target area, severity of condition, and other factors
Published in Current Pharmaceutical Design characterized BPC-157 as a modulator of the L-arginine/NO pathway, with effects on both endothelial NOS (eNOS) and inducible NOS (iNOS)
1,2,6 Neurologic manifestations are caused by progressive demyelination and can include peripheral neuropathy, areflexia, and the loss of proprioception and vibratory sense
As a distributor, you can benefit from wholesale offers while selecting OEM solutions to optimize costs